Search

Your search keyword '"Fulham, Michael"' showing total 794 results
Start Over Author "Fulham, Michael"

Refine your results

794 results on '"Fulham, Michael"'

153. Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease

Author

Dincer, Aylin, primary, Gordon, Brian A., additional, Hari-Raj, Amrita, additional, Keefe, Sarah J., additional, Flores, Shaney, additional, McKay, Nicole S., additional, Paulick, Angela M., additional, Shady Lewis, Kristine E., additional, Feldman, Rebecca L., additional, Hornbeck, Russ C., additional, Allegri, Ricardo, additional, Ances, Beau M., additional, Berman, Sarah B., additional, Brickman, Adam M., additional, Brooks, William S., additional, Cash, David M., additional, Chhatwal, Jasmeer P., additional, Farlow, Martin R., additional, la Fougère, Christian, additional, Fox, Nick C., additional, Fulham, Michael J., additional, Jack, Clifford R., additional, Joseph-Mathurin, Nelly, additional, Karch, Celeste M., additional, Lee, Athene, additional, Levin, Johannes, additional, Masters, Colin L., additional, McDade, Eric M., additional, Oh, Hwamee, additional, Perrin, Richard J., additional, Raji, Cyrus, additional, Salloway, Stephen P., additional, Schofield, Peter R., additional, Su, Yi, additional, Villemagne, Victor L., additional, Wang, Qing, additional, Weiner, Michael W., additional, Xiong, Chengjie, additional, Yakushev, Igor, additional, Morris, John C., additional, Bateman, Randall J., additional, and L.S. Benzinger, Tammie, additional

Published
2020
Full Text
View/download PDF

160. Simultaneous emission and transmission scanning in PET oncology: the effect of parameter estimation

Author

Meikle, Steven R., Eberl, Stefan, Hooper, Patrick K., and Fulham, Michael J.

Subjects
Parameter estimation -- Research, PET imaging -- Research, Oncology -- Research, Business, Electronics, Electronics and electrical industries
Abstract

We investigated potential sources of bias due to simultaneous emission and transmission (SET) scanning and their effect on parameter estimation in dynamic positron emission tomography (PET) oncology studies. The sources of bias considered include: i) variation in transmission spillover (into the emission window) throughout the field of view, ii) increased scatter arising from rod sources, and iii) inaccurate deadtime correction. Net bias was calculated as a function of the emission count rate and used to predict distortion in [18F]2-fluoro-2-deoxy-D-glucose (FDG) and [11C]thymidine tissue curves simulating the normal liver and metastatic involvement of the liver. The effect on parameter estimates was assessed by spectral analysis and compartmental modeling. The various sources of bias approximately cancel during the early part of the study when count rate is maximal. Scatter dominates in the latter part of the study, causing apparently decreased tracer clearance which is more marked for thymidine than for FDG. The irreversible disposal rate constant, [K.sub.i], was overestimated by 30% for thymidine. We conclude that SET has a potential role in dynamic FDG PET but is not suitable for 11C-labeled compounds. Index Terms - Oncology, positron emission tomography, transmission scanning.

Published
1997

162. Optimized sampling and parameter estimation for quantification in whole body PET

Author

Ho-Shon, Kevin, Feng, Dagan, Hawkins, Randall A., Meikle, Steven, Fulham, Michael J., and Li, Xianjin

Subjects
PET imaging -- Models, Least squares -- Usage, Biological sciences, Business, Computers, Health care industry
Abstract

Whole-body positron emission tomography (PET) has recently emerged as an important imaging tool for cancer detection and staging. Initial applications of the technique have been primarily qualitative. One of the major reasons is the limits imposed by kinetically undersampled data over the whole body, as opposed to the standard method of continuous dynamic sampling in one body location. In this paper, a new estimation method using weighted nonlinear least squares (WNLS) for the first bed position and Bayesian regression (BR) for subsequent positions is proposed. A general criterion for designing optimal sampling schedules which maximizes the measurement information with multiple bed positions is developed. The overall approach is illustrated with the problem of estimating the metabolic rate of glucose (MRGlu) in tumors at different axial positions (image bed positions) in the body by using computer simulations and patient data. The results show that estimates of MRGlu using sparse data and the optimized Bayesian approach are comparable with those obtained by standard methods and fully sampled data. This study demonstrates the potential of the technique described for quantification where several bed positions have to be used to image all the regions of interest (ROI).

Published
1996

163. 18F-FDG PET/CT Radiomics for Preoperative Prediction of Lymph Node Metastases and Nodal Staging in Gastric Cancer.

Author

Liu, Qiufang, Li, Jiaru, Xin, Bowen, Sun, Yuyun, Feng, Dagan, Fulham, Michael J., Wang, Xiuying, and Song, Shaoli

Subjects
LYMPHATIC metastasis, RADIOMICS, STOMACH cancer, COMPUTED tomography, GASTRECTOMY
Abstract

Objectives: The accurate assessment of lymph node metastases (LNMs) and the preoperative nodal (N) stage are critical for the precise treatment of patients with gastric cancer (GC). The diagnostic performance, however, of current imaging procedures used for this assessment is sub-optimal. Our aim was to investigate the value of preoperative 18F-FDG PET/CT radiomic features to predict LNMs and the N stage. Methods: We retrospectively collected clinical and 18F-FDG PET/CT imaging data of 185 patients with GC who underwent total or partial radical gastrectomy. Patients were allocated to training and validation sets using the stratified method at a fixed ratio (8:2). There were 2,100 radiomic features extracted from the 18F-FDG PET/CT scans. After selecting radiomic features by the random forest, relevancy-based, and sequential forward selection methods, the BalancedBagging ensemble classifier was established for the preoperative prediction of LNMs, and the OneVsRest classifier for the N stage. The performance of the models was primarily evaluated by the AUC and accuracy, and validated by the independent validation methods. Analysis of the feature importance and the correlation were also conducted. We also compared the predictive performance of our radiomic models to that with the contrast-enhanced CT (CECT) and 18F-FDG PET/CT. Results: There were 185 patients—127 men, 58 women, with the median age of 62, and an age range of 22–86 years. One CT feature and one PET feature were selected to predict LNMs and achieved the best performance (AUC: 82.2%, accuracy: 85.2%). This radiomic model also detected some LNMs that were missed in CECT (19.6%) and 18F-FDG PET/CT (35.7%). For predicting the N stage, four CT features and one PET feature were selected (AUC: 73.7%, accuracy: 62.3%). Of note, a proportion of patients in the validation set whose LNMs were incorrectly staged by CECT (57.4%) and 18F-FDG PET/CT (55%) were diagnosed correctly by our radiomic model. Conclusion: We developed and validated two machine learning models based on the preoperative 18F-FDG PET/CT images that have a predictive value for LNMs and the N stage in GC. These predictive models show a promise to offer a potentially useful adjunct to current staging approaches for patients with GC. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

168. Contributors

Author

Adam, M., primary, Alpert, Nathaniel M., additional, Anderson, J.R., additional, Andreasen, Nancy C., additional, Antonini, A., additional, Ardekani, Babak A., additional, Arndt, Stephan, additional, Ashburner, John, additional, Ashworth, Sharon, additional, Bailey, Dale L., additional, Baker, E., additional, Barnes, D.G., additional, Bench, C., additional, Bendriem, B., additional, Berdichevsky, D., additional, Biegon, A., additional, Blair, R.C., additional, Blomqvist, G., additional, Bloomfield, Peter M., additional, Ponto, Laura L. Boles, additional, Brakeman, Paul, additional, Braun, Michael, additional, Brooks, David J., additional, Brown, C.K., additional, Brown, W.D., additional, Bruckbauer, T., additional, Buckley, K.R., additional, Calonder, C., additional, Campbell, Gregory, additional, Carson, Richard E., additional, Chaly, Thomas, additional, Chan, G. L-Y., additional, Chen, Chin-Tu, additional, Cizadlo, Ted, additional, Cliffe, I.A., additional, Collins, D.L., additional, Cooper, Malcolm, additional, Crivello, F., additional, Crossnoe, M., additional, Cumming, Paul, additional, Cunningham, Vincent J., additional, Czernin, J., additional, Dahlbom, M., additional, Damasio, H., additional, DaSilva, J., additional, Witherspoon, Margaret E. Daube-, additional, DeJesus, O.T., additional, Delforge, J., additional, Dhawan, Vijay, additional, Dickhoven, S., additional, Diksic, Mirko, additional, Eberl, Stefan, additional, Egan, G.F., additional, Eidelberg, David, additional, Eriksson, Lars, additional, Evans, Alan C., additional, Fink, G.R., additional, Fischman, Alan J., additional, Fisher, Ronald E., additional, Fletcher, A., additional, Fontaine, A., additional, Ford, I., additional, Forse, G., additional, Frackowiak, R.S.J., additional, Frank, R.J., additional, Friston, K.J., additional, Frost, J. James, additional, Frouin, V., additional, Fujita, Hideaki, additional, Fujiwara, Takehiko, additional, Fukuda, H., additional, Fulham, Michael J., additional, Gee, Anthony D., additional, Gillings, N., additional, Gjedde, Albert, additional, Glaser, Robert, additional, Grabowski, T.J., additional, Graf, R., additional, Grafton, S.T., additional, Graham, Michael M., additional, Grasby, P., additional, Gunn, R.N., additional, Günther, I., additional, Hagisawa, S., additional, Haida, A., additional, Halber, M., additional, Hallett, Mark, additional, Hansen, Lars K., additional, Harris, Greg, additional, Haslam, Jane, additional, Hasselbalch, Steen, additional, Hatazawa, Jun, additional, Heiss, W.-D., additional, Herholz, K., additional, Herscovitch, Peter, additional, Herzog, H., additional, Hichwa, Richard D., additional, Hoh, C., additional, Holden, J.E., additional, Holm, Søren, additional, Holmes, A.P., additional, Holmes, C.J., additional, Hooper, Patrick K., additional, Houle, S., additional, Houser, D., additional, Huang, Sung-Cheng, additional, Hume, S.P., additional, Hurtig, Richard R., additional, Hussey, D., additional, Hutton, Brian F., additional, Iacoboni, M., additional, Ido, T., additional, Iida, Hidehiro, additional, Inoue, O., additional, Ishii, Kazunari, additional, Ishikawa, Tatsuya, additional, Itoh, H., additional, Itoh, Masatoshi, additional, Iwata, R., additional, Jadali, F., additional, Jagust, W., additional, Jivan, S., additional, Joliot, M., additional, Jones, A.K.P., additional, Jones, C., additional, Jones, Terry, additional, Kanno, Iwao, additional, Kao, Chien-Min, additional, Kapur, S., additional, Karbe, H., additional, Kessler, J., additional, Kilbourn, Michael R., additional, Kimura, Yuichi, additional, Kinahan, P.E., additional, Knorr, U., additional, Kobayashi, K., additional, Kops, E. Rota, additional, Kosugi, Yukio, additional, Kruger, Mark, additional, Kuwabara, Hiroto, additional, Lammertsma, Adriaan A., additional, Laurier, L., additional, Law, Ian, additional, Leenders, K.L., additional, Legg, B., additional, Levin, Z., additional, Lin, Kang-Ping, additional, Links, Jonathan M., additional, Lipinski, B., additional, Lopresti, B.J., additional, Löttgen, J., additional, Luthra, S.K., additional, Ma, Yilong, additional, Maguire, R.P., additional, Mahmood, K., additional, Malizia, Andrea L., additional, Mankoff, David A., additional, Marenco, Stefano, additional, Marrett, S., additional, Mathis, C.A., additional, Matsumura, Y., additional, Mazoyer, B., additional, Mazziotta, John C., additional, McCarron, J.A., additional, Meguro, K., additional, Meikle, Steven R., additional, Mejia, Marco A., additional, Mellet, E., additional, Meltzer, Carolyn Cidis, additional, Meyer, Ernst, additional, Millet, P., additional, Minoshima, S., additional, Mintun, M.A., additional, Missimer, J., additional, Miura, Shuichi, additional, Miyake, M., additional, Momose, Toshimitsu, additional, Mørch, Niels, additional, Morris, Evan D., additional, Morrish, Paul K., additional, Morrison, S., additional, Müller-Gärtner, H.W., additional, Murase, Kenya, additional, Muzi, Mark, additional, Myers, R., additional, Nakamura, Takashi, additional, Nariai, Tadashi, additional, Neelin, P., additional, Nickles, R.J., additional, Nishikawa, Junichi, additional, Nishizawa, Sadahiko, additional, Nutt, D.J., additional, O'Keefe, G.J., additional, O'Leary, Daniel S., additional, O'Sullivan, B.T., additional, O'Sullivan, Finbarr, additional, Oberschelp, W., additional, Ogawa, Toshihide, additional, Ono, S., additional, Osman, S., additional, Patlak, Clifford, additional, Paulson, Olaf B., additional, Pawlik, Gunter, additional, Petit, L., additional, Pietrzyk, U., additional, Pike, V.W., additional, Poline, J.-B., additional, Poole, K., additional, Price, J.C., additional, Psylla, M., additional, Pyzalski, Robert, additional, Rajeswaran, S., additional, Rakshi, James S., additional, Ranicar, Alex, additional, Rauch, Scott L., additional, Remy, P., additional, Reutens, David C., additional, Roberts, Andy, additional, Rosenqvist, G., additional, Rottenberg, D.A., additional, Rousset, Olivier G., additional, Ruth, T.J., additional, Sadato, Norihiro, additional, Samson, Y., additional, Sasaki, H., additional, Sase, Mikiya, additional, Sashin, D., additional, Schaper, K., additional, Schlaug, G., additional, Schnorr, L., additional, Seitz, R.J., additional, Senda, Michio, additional, Shelton, S.E., additional, Shields, Anthony F., additional, Shimosegawa, Eku, additional, Shiraishi, Masahiro, additional, Shrager, Richard, additional, Sidtis, J.J., additional, Simpson, N.R., additional, Smith, D., additional, Smith, Donald F., additional, Snow, B.J., additional, Snyder, Abraham Z., additional, Sossi, V., additional, Spelle, L., additional, Spence, Alexander, additional, Strother, S.C., additional, Stumpf, Martin J., additional, Suganami, Yusuke, additional, Svarer, Claus, additional, Swerdloff, S.J., additional, Syrota, A., additional, Taguchi, A., additional, Talarico, E., additional, Taylor, Chris, additional, Tellman, L., additional, Thiel, A., additional, Danguy, H. J. Tochon-, additional, Toga, Arthur W., additional, Toussaint, P.-J., additional, Townsend, D.W., additional, Toyama, Hinako, additional, Trébossen, R., additional, Tzourio, N., additional, Uchiyama, A., additional, Uemura, Kazuo, additional, Uno, H., additional, Vafaee, M., additional, Vingerhoets, F.J.G., additional, Vontobel, P., additional, Wagner, R., additional, Watabe, Hiroshi, additional, Watkins, G. Leonard, additional, Watson, J.D.G., additional, Wernick, Miles, additional, Wienhard, K., additional, Wilson, A.A., additional, Wilson, S., additional, Wollenweber, Scott D., additional, Wong, Dean F., additional, Woods, Roger P., additional, Worsley, K.J., additional, Yan, Yuchen, additional, Yanai, K., additional, Yang, J., additional, Yap, Jeffrey T., additional, Yu, D.C., additional, Zeien, Gene, additional, Zhou, Y., additional, and Zubieta, Jon Kar, additional

Published
1996
Full Text
View/download PDF

176. A Critical Role for Intratumoral and Circulating LAG3 in Classical Hodgkin Lymphoma: Analysis from the Rathl Prospective Phase III International Clinical Trial

Author

Abro, Emad Uddin, primary, Law, Soi C, additional, Keane, Colm, additional, Birch, Simone, additional, Sabdia, Muhammed Bilal, additional, Tobin, Joshua W.D., additional, Johnson, Peter, additional, Trotman, Judith, additional, Berkahn, Leanne, additional, Fulham, Michael, additional, Anderson, Richard A, additional, Saunderson, Anne L, additional, Gunawardana, Jay, additional, Cross, Donna, additional, Hernandez, Annette, additional, Halliday, Sarah-Jane, additional, Bird, Robert, additional, Law, W P, additional, Gill, Devinder, additional, and Gandhi, Maher K, additional

Published
2018
Full Text
View/download PDF

181. Pituitary microadenomas: a PET study

Author

De Souza, Bryan, Brunetti, Arturo, Fulham, Michael J., Brooks, Rodney A., DeMichele, Domenic, Cook, Paul, Nieman, Lynnette, Doppman, John L., Oldfield, Edward H., and Di Chiro, Giovanni

Subjects
Brain tumors -- Diagnosis, Magnetic resonance imaging, PET imaging, Contrast media, Pituitary gland tumors -- Diagnosis, Health
Abstract

The pituitary gland is sometimes afflicted with microadenomas, small benign tumors found in epithelial tissue. Noninvasive assessment of these tumors is required. Presently, computed tomography (CT) and magnetic resonance (MR) imaging are the two diagnostic techniques used for this purpose. Positron emission tomography (PET) is currently used to measure metabolic and physiological functions in the brain. Some have suggested that it may be of use in tumor detection. PET uses a computer to form images; the computer uses data transmitted from radioactive materials that have been incorporated into the brain's biochemistry. Fluorine-18-2-flurodeoxyglucose (FDG) is one of the materials used in PET. By detecting the uptake of FDG, PET may reveal the presence of a tumor. This study assessed results of PET-FDG from 20 patients with pituitary microadenomas, and compared them with CT and MR results. FDG uptake was also measured in healthy volunteers. Little uptake of FDG was observed in the healthy volunteers. Of the 18 patients studied with CT, only 7 were correctly diagnosed. MR results were better; 13 patients were correctly diagnosed, 2 patients' results were inconclusive, and 4 patients' results were false-negatives (indicated normal results when tumors were actually present). PET was able to correctly diagnose 12 patients, but there were 7 false-negative results. However, PET detected tumors in four cases that MR had not detected and revealed a 2 millimeter lesion that was questionable according to MR. These results indicate that PET can be useful in diagnosing pituitary microadenomas. It is more reliable when used as a complement to MR imaging. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1990

185. The combined therapeutic effects of 131iodine-labeled multifunctional copper sulfide-loaded microspheres in treating breast cancer

Author

Liu, Qiufang, primary, Qian, Yuyi, additional, Li, Panli, additional, Zhang, Sihang, additional, Wang, Zerong, additional, Liu, Jianjun, additional, Sun, Xiaoguang, additional, Fulham, Michael, additional, Feng, Dagan, additional, Chen, Zhigang, additional, Song, Shaoli, additional, Lu, Wei, additional, and Huang, Gang, additional

Published
2018
Full Text
View/download PDF

187. Impact of salvage treatment modalities in patients with positive FDG-PET/CT after R-CHOP chemotherapy for aggressive B-cell non-Hodgkin lymphoma

Author

Chin, Vicky, primary, Fulham, Michael, additional, Hertzberg, Mark, additional, Jackson, Michael, additional, Lindeman, Robert, additional, Brighton, Timothy, additional, Kidson-Gerber, Giselle, additional, Wegner, Eva A, additional, Cheung, Carol, additional, MacCallum, Susan, additional, Williams, Janet, additional, and Thompson, Stephen R, additional

Published
2018
Full Text
View/download PDF

192. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study

Author

van Zandwijk, Nico, primary, Pavlakis, Nick, additional, Kao, Steven C, additional, Linton, Anthony, additional, Boyer, Michael J, additional, Clarke, Stephen, additional, Huynh, Yennie, additional, Chrzanowska, Agata, additional, Fulham, Michael J, additional, Bailey, Dale L, additional, Cooper, Wendy A, additional, Kritharides, Leonard, additional, Ridley, Lloyd, additional, Pattison, Scott T, additional, MacDiarmid, Jennifer, additional, Brahmbhatt, Himanshu, additional, and Reid, Glen, additional

Published
2017
Full Text
View/download PDF

193. Synthesis and pharmacological evaluation of [18F]PBR316: a novel PET ligand targeting the translocator protein 18 kDa (TSPO) with low binding sensitivity to human single nucleotide polymorphism rs6971Electronic supplementary information (ESI) available. See DOI: 10.1039/d1md00035g

Author

Mattner, Filomena, Katsifis, Andrew, Bourdier, Thomas, Loc'h, Christian, Berghofer, Paula, Fookes, Christopher, Hung, Tzong-Tyng, Jackson, Timothy, Henderson, David, Pham, Tien, Lee, Brendan J., Shepherd, Rachael, Greguric, Ivan, Wyatt, Naomi, Le, Thanh, Poon, Jackson, Power, Carl, and Fulham, Michael

Abstract

Radiopharmaceuticals that target the translocator protein 18 kDa (TSPO) have been investigated with positron emission tomography (PET) to study neuroinflammation, neurodegeneration and cancer. We have developed the novel, achiral, 2-phenylimidazo[1,2-a]pyridine, PBR316 that targets the translocator protein 18 kDa (TSPO) that addresses some of the limitations inherent in current TSPO ligands; namely specificity in binding, blood brain barrier permeability, metabolism and insensitivity to TSPO binding in subjects as a result of rs6971 polymorphism. PBR316 has high nanomolar affinity (4.7–6.0 nM) for the TSPO, >5000 nM for the central benzodiazepine receptor (CBR) and low sensitivity to rs6971 polymorphism with a low affinity binders (LABs) to high affinity binders (HABs) ratio of 1.5. [18F]PBR316 was prepared in 20 ± 5% radiochemical yield, >99% radiochemical purity and a molar activity of 160–400 GBq μmol−1. Biodistribution in rats showed high uptake of [18F]PBR316 in organs known to express TSPO such as heart (3.9%) and adrenal glands (7.5% ID per g) at 1 h. [18F]PBR316 entered the brain and accumulated in TSPO-expressing regions with an olfactory bulb to brain ratio of 3 at 15 min and 7 at 4 h. Radioactivity was blocked by PK11195 and Ro 5-4864 but not Flumazenil. Metabolite analysis showed that radioactivity in adrenal glands and the brain was predominantly due to the intact radiotracer. PET–CT studies in mouse-bearing prostate tumour xenografts indicated biodistribution similar to rats with radioactivity in the tumour increasing with time. [18F]PBR316 shows in vitrobinding that is insensitive to human polymorphism and has specific and selective in vivobinding to the TSPO. [18F]PBR316 is suitable for further biological and clinical studies.

Published
2021
Full Text
View/download PDF

194. PET-CT for staging & early response:results from 'Response Adapted Therapy in Advanced Hodgkin Lymphoma' (RATHL) (CRUK/07/033)

Author

Barrington, Sally F, Kirkwood, Amy A, Franceschetto, Antonella, Fulham, Michael J, Roberts, Thomas H, Almquist, Helén, Brun, Eva, Hjorthaug, Karin, Viney, Zaid N, Pike, Lucy C, Federico, Massimo, Luminari, Stefano, Radford, John, Trotman, Judith, Fosså, Alexander, Berkahn, Leanne, Molin, Daniel, D'Amore, Francesco, Sinclair, Donald A, Smith, Paul, O'Doherty, Michael J, Stevens, Lindsey, and Johnson, Peter W

Abstract

International guidelines recommend PET-CT should replace CT in Hodgkin Lymphoma (HL). The aims of this study were to i) compare PET-CT with CT for staging and ii) measure agreement between expert and local readers, using a five-point scale (Deauville criteria), to adapt treatment in a clinical trial 'Response Adapted Therapy in Advanced Hodgkin Lymphoma' (RATHL) www.cancer.gov/clinicaltrials, reference NCT00678327. Patients were staged for the trial using clinical assessment, CT and bone marrow biopsy (RATHL stage). PET-CT was performed at baseline (PET0) and after 2 chemotherapy cycles (PET2) in a response-adapted design. PET-CT was reported centrally by experts at 5 national core labs. Local readers optionally scored PET2 scans. The RATHL and PET-CT stages were compared. Agreement amongst experts and between expert and local readers was measured. RATHL and PET0 stage were concordant in 938 (80%) patients. PET-CT upstaged 159 (14%) and downstaged 74 (6%) patients. Upstaging by extranodal disease in bone marrow (92), lung (11) or multiple sites (12) on PET-CT accounted for most discrepancies. Follow-up of discrepant findings confirmed the PET characterisation of lesions in the vast majority. Five patients were upstaged by marrow biopsy; 7 by contrast-enhanced CT in bowel and/or liver or spleen. PET2 agreement amongst experts (140 scans) with kappa (95% CI) of 0.84 (0.76 - 0.91) was very good and between experts and local readers (300 scans) at 0.77 (0.68-0.86) was good. These results confirm PET-CT as the modern standard for staging HL and that response assessment using Deauville criteria is robust enabling translation of RATHL results into clinical practice.

Published
2016

198. Acute unilateral peripheral vestibulopathy in neurosyphilis

Author

Young, Allison S., primary, Carroll, Antonia S., additional, Welgampola, Miriam S., additional, McCluskey, Peter J., additional, van Hal, Sebastian J., additional, Thompson, Elizabeth O., additional, Burn, Juliet, additional, Fulham, Michael J., additional, and Halmagyi, G. Michael, additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results